TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Closed-Loop Delivery of Propofol and Remifentanil: Sparing Effect of Dexmedetomidine
Brief Summary: The main objective if to evaluate the sparing effect of dexmedetomidine on the doses of propofol and remifentanil.


Options:
A: Arm Label: Active Clonidine and Active ASA; Type: EXPERIMENTAL; Interventions: Drug: Active Clonidine, Drug: Active ASA | Arm Label: Active Clonidine and Placebo ASA; Type: EXPERIMENTAL; Interventions: Drug: Active Clonidine, Drug: Placebo ASA | Arm Label: Placebo Clonidine and Active ASA; Type: EXPERIMENTAL; Interventions: Drug: Placebo Clonidine, Drug: Active ASA | Arm Label: Placebo Clonidine and Placebo ASA; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Clonidine, Drug: Placebo ASA | Intervention Type: DRUG; Name: Active Clonidine; Assigned to Arm(s): Active Clonidine and Active ASA, Active Clonidine and Placebo ASA | Intervention Type: DRUG; Name: Placebo Clonidine; Assigned to Arm(s): Placebo Clonidine and Active ASA, Placebo Clonidine and Placebo ASA | Intervention Type: DRUG; Name: Active ASA; Assigned to Arm(s): Active Clonidine and Active ASA, Placebo Clonidine and Active ASA | Intervention Type: DRUG; Name: Placebo ASA; Assigned to Arm(s): Active Clonidine and Placebo ASA, Placebo Clonidine and Placebo ASA
B: N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: NaCl 9/00 | Arm Label: dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: dexmedetomidine | Intervention Type: DRUG; Name: NaCl 9/00; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: dexmedetomidine; Assigned to Arm(s): dexmedetomidine
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Metoprolol controlled release (CR) | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metoprolol controlled release (CR); Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving the Quality of Asthma Care Using the Internet
Brief Summary: It is important for people with asthma to become involved in their asthma care and management. This study will evaluate an interactive Web site that provides tailored feedback and information to asthma patients and encourages them to ask their doctor specific questions about their asthma care.


Options:
A: Arm Label: I; Type: EXPERIMENTAL; Interventions: Behavioral: Feedback of patient adherence information | Arm Label: II; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active control group | Intervention Type: BEHAVIORAL; Name: Feedback of patient adherence information; Assigned to Arm(s): I | Intervention Type: BEHAVIORAL; Name: Active control group; Assigned to Arm(s): II
B: Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Video-based guidance | Arm Label: Treatment Group; Type: ACTIVE_COMPARATOR; Interventions: Device: CapMedic smart inhaler device | Intervention Type: DEVICE; Name: CapMedic smart inhaler device; Assigned to Arm(s): Treatment Group | Intervention Type: BEHAVIORAL; Name: Video-based guidance; Assigned to Arm(s): Control Group
C: Arm Label: intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: intervention group | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: intervention group; Assigned to Arm(s): intervention group
D: Arm Label: Asthma Feedback; Type: EXPERIMENTAL; Interventions: Behavioral: Asthma Feedback | Arm Label: Preventive Feedback; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Asthma Feedback | Intervention Type: BEHAVIORAL; Name: Asthma Feedback; Assigned to Arm(s): Asthma Feedback, Preventive Feedback

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: St. Vincent's Screening To Prevent Heart Failure (STOP-HF) Study Using Natriuretic Peptides to Identify and Prevent Progression of Left Ventricular Dysfunction in Community Based, Asymptomatic, At-risk Individuals.
Brief Summary: The STOP-HF study is a prospective, randomized, controlled trial recruiting asymptomatic individuals with risk factors for left ventricular dysfunction from 50 primary care clinics in Dublin and south east Ireland. It is designed to determine whether using natriuretic peptide measurement as a screening tool following a general cardiovascular risk factor screen will reduce the prevalence and severity of ventricular dysfunction in conjunction with specialist follow-up at St. Vincent's University Hospital.


Options:
A: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: OTHER; Interventions: Other: Intervention Care | Intervention Type: OTHER; Name: Intervention Care; Assigned to Arm(s): Intervention
B: Arm Label: Dabigatran dose 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 2 | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: Dabigatran dose 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 1 | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran dose 1; Assigned to Arm(s): Dabigatran dose 1 | Intervention Type: DRUG; Name: Dabigatran dose 2; Assigned to Arm(s): Dabigatran dose 2
C: Intervention Type: PROCEDURE; Name: BNP-guided care in addition to multidisciplinary management; Assigned to Arm(s): N/A
D: Arm Label: NT-proBNP guided treatment group; Type: ACTIVE_COMPARATOR; Interventions: Device: NT-proBNP measurements | Arm Label: Clinically guided arm; Type: PLACEBO_COMPARATOR; Interventions: Device: NT-proBNP measurements | Intervention Type: DEVICE; Name: NT-proBNP measurements; Assigned to Arm(s): Clinically guided arm, NT-proBNP guided treatment group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: St. Vincent's Screening To Prevent Heart Failure (STOP-HF) Study Using Natriuretic Peptides to Identify and Prevent Progression of Left Ventricular Dysfunction in Community Based, Asymptomatic, At-risk Individuals.
Brief Summary: The STOP-HF study is a prospective, randomized, controlled trial recruiting asymptomatic individuals with risk factors for left ventricular dysfunction from 50 primary care clinics in Dublin and south east Ireland. It is designed to determine whether using natriuretic peptide measurement as a screening tool following a general cardiovascular risk factor screen will reduce the prevalence and severity of ventricular dysfunction in conjunction with specialist follow-up at St. Vincent's University Hospital.


Options:
A: Arm Label: SOC; Type: PLACEBO_COMPARATOR; Interventions: Other: Drug therapy for HF | Arm Label: NT-proBNP arm; Type: ACTIVE_COMPARATOR; Interventions: Other: NT-proBNP guided HF therapy | Intervention Type: OTHER; Name: Drug therapy for HF; Assigned to Arm(s): SOC | Intervention Type: OTHER; Name: NT-proBNP guided HF therapy; Assigned to Arm(s): NT-proBNP arm
B: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: OTHER; Interventions: Other: Intervention Care | Intervention Type: OTHER; Name: Intervention Care; Assigned to Arm(s): Intervention
C: Arm Label: Usual Care; Type: EXPERIMENTAL; Interventions: Other: Usual Care | Arm Label: Biomarker-Guided Care; Type: EXPERIMENTAL; Interventions: Device: Biomarker-guided care NT-proBNP | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care | Intervention Type: DEVICE; Name: Biomarker-guided care NT-proBNP; Assigned to Arm(s): Biomarker-Guided Care
D: Arm Label: Heart Failure; Type: N/A; Interventions: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Heliox and Posture Optimize Action of Nebulization With Bronchodilators for Asthma Attacks. Randomized Trial.
Brief Summary: The purpose of this study is to verify that nebulization with bronchodilators associated with heliox gas (helium + oxygen) and the posture of a leaning forward truck is effective in patients with an asthma attack.


Options:
A: Arm Label: heliox; Type: EXPERIMENTAL; Interventions: Other: HELIOX | Arm Label: heliox+posture; Type: EXPERIMENTAL; Interventions: Other: HELIOX+POSTURE | Arm Label: oxygen+posture; Type: EXPERIMENTAL; Interventions: Other: OXYGEN + POSTURE | Arm Label: oxygen; Type: ACTIVE_COMPARATOR; Interventions: Other: OXYGEN | Intervention Type: OTHER; Name: HELIOX; Assigned to Arm(s): heliox | Intervention Type: OTHER; Name: OXYGEN; Assigned to Arm(s): oxygen | Intervention Type: OTHER; Name: HELIOX+POSTURE; Assigned to Arm(s): heliox+posture | Intervention Type: OTHER; Name: OXYGEN + POSTURE; Assigned to Arm(s): oxygen+posture
B: Arm Label: EzPAP; Type: EXPERIMENTAL; Interventions: Drug: EzPAP | Arm Label: Standard care; Type: SHAM_COMPARATOR; Interventions: Other: Standard Care | Intervention Type: DRUG; Name: EzPAP; Assigned to Arm(s): EzPAP | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): Standard care
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Comparator: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: montelukast sodium | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: montelukast sodium | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): 2, 3 | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): 1
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MN-221 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: MN-221; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Weaning Process in Elderly Intubated Patients Submitted to Inspiratory Muscle Training
Brief Summary: Background: the objective of the present inquiry was to evaluate the weaning process in intubated older people subjected to inspiratory muscle training and to correlate the predictors of ventilatory interruption with its success.

Methods: the patients were divided randomly into an experimental group (EG, n=14; age=82±4 years) that received conventional physiotherapy plus inspiratory muscle training (IMT) with threshold IMT® and a control group (CG, n=14; age=81±6 years) that received only conventional physiotherapy. The predictors evaluates were the maximum inspiratory pressure (MIP) and the index of Tobin (IT). The protocol for muscle training consisted of an initial load of 30% MIP, which was increased by 10% daily; training was administered for five minutes, twice a day, seven times a week with supplemental oxygen for the entire period from the decision to wean up to extubation.


Options:
A: Arm Label: Control Group; Type: SHAM_COMPARATOR; Interventions: Other: Manual Diaphragm release technique (sham) | Arm Label: Intevention Group; Type: EXPERIMENTAL; Interventions: Other: Manual Diaphragm Release Technique | Intervention Type: OTHER; Name: Manual Diaphragm Release Technique; Assigned to Arm(s): Intevention Group | Intervention Type: OTHER; Name: Manual Diaphragm release technique (sham); Assigned to Arm(s): Control Group
B: N/A
C: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Behavioral: Respiratory rehabilitation exercise training | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Respiratory rehabilitation exercise training; Assigned to Arm(s): Experimental group
D: Intervention Type: OTHER; Name: inspiratory muscle training; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of a Combined Strategy Addressed to Practitioners and COPD Patients: Information Feed-back and Health Education, to Improve Clinical Control and Quality of Life
Brief Summary: Main objective:

Evaluate the effectiveness of a combined strategy addressed to health care workers and patients, in relation to improving clinical control and patient's quality of life.It includes a feed-back about the health status of the patients, an education plan addressed to practitioners based in a CPG and in health education


Options:
A: Arm Label: Case method education in COPD; Type: EXPERIMENTAL; Interventions: Behavioral: Case method education in COPD | Arm Label: Traditional education in COPD; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Traditional education in COPD | Intervention Type: BEHAVIORAL; Name: Case method education in COPD; Assigned to Arm(s): Case method education in COPD | Intervention Type: BEHAVIORAL; Name: Traditional education in COPD; Assigned to Arm(s): Traditional education in COPD
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Intervention
C: Intervention Type: OTHER; Name: Implementation of Clinical Practice Guidelines (GPC) and Health Education Program; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling and Nicotine replacement (CN) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling, Nicotine replacement and Bupropion (CNB) | Intervention Type: BEHAVIORAL; Name: Counseling and Nicotine replacement (CN); Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Counseling, Nicotine replacement and Bupropion (CNB); Assigned to Arm(s): 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Fixed-Dose, Randomized, Double-Blind, Placebo-Controlled Study of LY2216684 in Pediatric Patients With Attention Deficit/Hyperactivity Disorder
Brief Summary: The primary purpose of your child's participation in this study is to determine whether LY2216684 can help pediatric patients with attention-deficit/hyperactivity disorder (ADHD); and assess the safety of LY2216684 and any side effects that might be associated with it.


Options:
A: Arm Label: Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (tablet), Drug: Placebo (capsule) | Arm Label: LY2216684 (0.1 mg/kg/day); Type: EXPERIMENTAL; Interventions: Drug: LY2216684 | Arm Label: LY2216684 (0.2 mg/kg/day); Type: EXPERIMENTAL; Interventions: Drug: LY2216684 | Arm Label: LY2216684 (0.3 mg/kg/day); Type: EXPERIMENTAL; Interventions: Drug: LY2216684 | Intervention Type: DRUG; Name: LY2216684; Assigned to Arm(s): LY2216684 (0.1 mg/kg/day), LY2216684 (0.2 mg/kg/day), LY2216684 (0.3 mg/kg/day) | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Methylphenidate | Intervention Type: DRUG; Name: Placebo (tablet); Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Placebo (capsule); Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Low Dose Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Arm Label: Medium Dose Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Arm Label: High Dose Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Low Dose Methylphenidate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Medium Dose Methylphenidate | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): High Dose Methylphenidate
C: Intervention Type: DRUG; Name: methylphenidate hydrochloride; Assigned to Arm(s): N/A
D: Arm Label: Methylphenidate Transdermal System (MTS); Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Transdermal System | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate Transdermal System (MTS) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Fixed-Dose, Randomized, Double-Blind, Placebo-Controlled Study of LY2216684 in Pediatric Patients With Attention Deficit/Hyperactivity Disorder
Brief Summary: The primary purpose of your child's participation in this study is to determine whether LY2216684 can help pediatric patients with attention-deficit/hyperactivity disorder (ADHD); and assess the safety of LY2216684 and any side effects that might be associated with it.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): 1
B: Arm Label: Focalin XR then Adderall XR; Type: EXPERIMENTAL; Interventions: Drug: Dexmethylphenidate, Drug: Mixed Amphetamine Salts, ER, Drug: placebo | Arm Label: Adderall XR then Focalin XR; Type: EXPERIMENTAL; Interventions: Drug: Dexmethylphenidate, Drug: Mixed Amphetamine Salts, ER, Drug: placebo | Intervention Type: DRUG; Name: Dexmethylphenidate; Assigned to Arm(s): Adderall XR then Focalin XR, Focalin XR then Adderall XR | Intervention Type: DRUG; Name: Mixed Amphetamine Salts, ER; Assigned to Arm(s): Adderall XR then Focalin XR, Focalin XR then Adderall XR | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Adderall XR then Focalin XR, Focalin XR then Adderall XR
C: Arm Label: Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (tablet), Drug: Placebo (capsule) | Arm Label: LY2216684 (0.1 mg/kg/day); Type: EXPERIMENTAL; Interventions: Drug: LY2216684 | Arm Label: LY2216684 (0.2 mg/kg/day); Type: EXPERIMENTAL; Interventions: Drug: LY2216684 | Arm Label: LY2216684 (0.3 mg/kg/day); Type: EXPERIMENTAL; Interventions: Drug: LY2216684 | Intervention Type: DRUG; Name: LY2216684; Assigned to Arm(s): LY2216684 (0.1 mg/kg/day), LY2216684 (0.2 mg/kg/day), LY2216684 (0.3 mg/kg/day) | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Methylphenidate | Intervention Type: DRUG; Name: Placebo (tablet); Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Placebo (capsule); Assigned to Arm(s): Placebo
D: Arm Label: Methylphenidate Transdermal System (MTS); Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Transdermal System | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate Transdermal System (MTS) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India
Brief Summary: The primary study hypothesis wasthat a two-dose human papillomavirus (HPV) vaccine regimen would offer similar immunogenicity and protection as that of a three-dose regimen to girls against persistent HPV infection and cervical neoplasia caused by HPV types included in the vaccine. The Government of India stopped vaccination in all the HPV vaccine trials in the country in April 2010 due to reasons not related to this study.


Options:
A: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix vaccine | Arm Label: Engerix-B Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Engerix-B vaccine | Intervention Type: BIOLOGICAL; Name: Cervarix vaccine; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Engerix-B vaccine; Assigned to Arm(s): Engerix-B Group
B: Arm Label: 3-dose; Type: ACTIVE_COMPARATOR; Interventions: Biological: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) | Arm Label: 2-dose; Type: EXPERIMENTAL; Interventions: Biological: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) | Arm Label: 2 doses by default; Type: EXPERIMENTAL; Interventions: Biological: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) | Arm Label: Single-dose; Type: EXPERIMENTAL; Interventions: Biological: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) | Arm Label: Unvaccinated; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®); Assigned to Arm(s): 2 doses by default, 2-dose, 3-dose, Single-dose
C: Intervention Type: BIOLOGICAL; Name: HPV-16/18 L1/AS04; Assigned to Arm(s): N/A
D: Arm Label: Cervarix-12 Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix TM | Arm Label: Cervarix-6 Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Cervarix TM | Intervention Type: BIOLOGICAL; Name: Cervarix TM; Assigned to Arm(s): Cervarix-12 Group | Intervention Type: BIOLOGICAL; Name: Cervarix TM; Assigned to Arm(s): Cervarix-6 Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Grains Reduce Adiposity and Improve Nutrition Study (GRAINS) Increased Whole Grain Intake - Beneficial Effects on Visceral Adiposity, Vascular Function and Glucose Metabolism/Insulin Resistance
Brief Summary: Whole grain intake beneficially affects body weight, body fat and glucose metabolism, and the investigators' previous work has shown that a high whole grain intake significantly reduced body fat in the abdominal region as measured by dual energy X-ray absorptiometry (DEXA) compared to a refined grain intake. Additional research is needed with regard to the mechanisms by which whole grains may affect visceral adiposity and the adipokines, which have been associated with risk for insulin resistance and type 2 diabetes. Therefore the proposed study aims to address these issues and in addition, includes exploratory work with adipocytes in cell culture to evaluate the effects of whole grains on adipocyte function.

Hypothesis:

There will be a greater reduction in visceral adiposity, indicators of insulin resistance (HOMA score), improvement in inflammatory status and improvement in adipokine levels after six weeks of a weight stable period and after six weeks of weight loss in subjects consuming 6-9 servings compared to 0 servings of whole grains per day.


Options:
A: Arm Label: Usual care group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: diet group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 50g-ONOG plus diet group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: organic naked oat with whole germ (ONOG) | Arm Label: 100g-ONOG plus diet group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: organic naked oat with whole germ (ONOG) | Intervention Type: DIETARY_SUPPLEMENT; Name: organic naked oat with whole germ (ONOG); Assigned to Arm(s): 100g-ONOG plus diet group, 50g-ONOG plus diet group
B: Arm Label: Refined grain; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Refined grain | Arm Label: Whole grain diet; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Whole grain diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Whole grain diet; Assigned to Arm(s): Whole grain diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Refined grain; Assigned to Arm(s): Refined grain
C: Intervention Type: DIETARY_SUPPLEMENT; Name: Ls-33; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Whole Grain Foods; Assigned to Arm(s): N/A

Answer: B